Compare Crispr Therapeutics AG (CRSP) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Global X Autonomous & Electric Vehicles — how do they compare? Crispr Therapeutics AG trades at $50.55 (market cap $4.97B), while Global X Autonomous & Electric Vehicles trades at $35.2. The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | DRIV | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Sector/Thematic |
52-Week High | $76.78 | $42.53 |
52-Week Low | $44.34 | $23.67 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
DRIV trades at $35.37, down 3.2% on the day amid a bearish technical signal. The stock faces selling pressure with moving averages indicating a downtrend, though oversold RSI levels suggest potential near-term support. Recent news highlights strong global EV sales growth and China's aggressive expansion, providing a favorable industry backdrop for this electric vehicle-focused ETF.
The outlook remains cautious due to technical weakness, though industry momentum from rising EV adoption offers long-term growth potential. Key risks include regulatory uncertainty around Chinese vehicles and potential tariff impacts. Investors should monitor technical levels for stabilization signs amid volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
